Mark C Kelley, M.D.

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

1. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Nat Commun : 10582
   › Primary publication · 26822383 (PubMed) · PMC4740184 (PubMed Central)
2. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma. Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB (2016) Pigment Cell Melanoma Res 29(1): 101-3
   › Primary publication · 26176864 (PubMed)
3. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2015) Clin Cancer Res 21(23): 5338-48
   › Primary publication · 26152738 (PubMed) · PMC4668227 (PubMed Central)
4. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Johnson DB, Puzanov I, Kelley MC (2015) Immunotherapy 7(6): 611-9
   › Primary publication · 26098919 (PubMed) · PMC4519012 (PubMed Central)
5. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. Johnson AS, Crandall H, Dahlman K, Kelley MC (2015) J Am Coll Surg 220(4): 581-93.e1
   › Primary publication · 25797743 (PubMed)
6. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL (2014) J Clin Invest 124(12): 5490-502
   › Primary publication · 25401474 (PubMed) · PMC4348968 (PubMed Central)
7. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A (2015) Cancer Res 75(1): 181-93
   › Primary publication · 25398437 (PubMed) · PMC4286469 (PubMed Central)
8. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer. Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson VG, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Yankeelov TE (2015) Invest Radiol 50(4): 195-204
   › Primary publication · 25360603 (PubMed) · PMC4471951 (PubMed Central)
9. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women. Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Fadiel A, Fair AM, Sanderson M, Shu XO, Kelley MC, Zheng W (2014) Clin Breast Cancer 14(6): 417-25
   › Primary publication · 24970715 (PubMed) · PMC4253543 (PubMed Central)
10. Melanoma, version 4.2014. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M, National Comprehensive Cancer Network (2014) J Natl Compr Canc Netw 12(5): 621-9
    › Primary publication · 24812131 (PubMed)
11. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA (2013) Cancer Immunol Res 1(6): 373-7
    › Primary publication · 24490176 (PubMed) · PMC3905602 (PubMed Central)
12. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS (2014) Cancer Discov 4(1): 80-93
    › Primary publication · 24265155 (PubMed) · PMC3936420 (PubMed Central)
13. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu XO, Kelley MC, Zheng W, Long J (2013) Carcinogenesis 34(10): 2240-3
    › Primary publication · 23715497 (PubMed) · PMC3786378 (PubMed Central)
14. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE (2014) Magn Reson Med 71(4): 1592-602
    › Primary publication · 23661583 (PubMed) · PMC3742614 (PubMed Central)
15. Adjuvant radiation therapy increases disease-free survival in stage IB Merkel cell carcinoma. Sexton KW, Poteet SP, Hill JB, Schmidt A, Patel A, Del Corral GA, Axt J, Kelley MC, Thayer WP, Shack RB (2014) Ann Plast Surg 73(5): 531-4
    › Primary publication · 23657045 (PubMed)
16. Melanoma, version 2.2013: featured updates to the NCCN guidelines. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M, National Comprehensive Cancer Network (NCCN) (2013) J Natl Compr Canc Netw 11(4): 395-407
    › Primary publication · 23584343 (PubMed)
17. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2013) EMBO Mol Med 5(1): 149-66
    › Primary publication · 23180582 (PubMed) · PMC3569660 (PubMed Central)
18. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W (2012) PLoS One 7(4): e35309
    › Primary publication · 22536370 (PubMed) · PMC3335021 (PubMed Central)
19. Melanoma. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, National Comprehensive Cancer Network (2012) J Natl Compr Canc Netw 10(3): 366-400
    › Primary publication · 22393197 (PubMed)
20. RAF265 inhibits the growth of advanced human melanoma tumors. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A (2012) Clin Cancer Res 18(8): 2184-98
    › Primary publication · 22351689 (PubMed) · PMC3724517 (PubMed Central)
21. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, Elashoff R, Mozzillo N, Kelley MC, Thompson JF, Lee JE, Hoon DS (2012) Ann Surg 255(2): 357-62
    › Primary publication · 22202581 (PubMed) · PMC3320770 (PubMed Central)
22. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE (2012) Magn Reson Med 68(1): 261-71
    › Primary publication · 22127821 (PubMed) · PMC3291742 (PubMed Central)
23. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) Nature 480(7377): 387-90
    › Primary publication · 22113612 (PubMed) · PMC3266695 (PubMed Central)
24. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE (2011) Phys Med Biol 56(17): 5753-69
    › Primary publication · 21841212 (PubMed) · PMC3176673 (PubMed Central)
25. Development of a spatially offset Raman spectroscopy probe for breast tumor surgical margin evaluation. Keller MD, Vargis E, de Matos Granja N, Wilson RH, Mycek MA, Kelley MC, Mahadevan-Jansen A (2011) J Biomed Opt 16(7): 077006
    › Primary publication · 21806286 (PubMed) · PMC3144975 (PubMed Central)
26. Protein signatures for survival and recurrence in metastatic melanoma. Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM (2011) J Proteomics 74(7): 1002-14
    › Primary publication · 21549228 (PubMed) · PMC3178099 (PubMed Central)
27. Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium. Long J, Cai Q, Shu XO, Qu S, Li C, Zheng Y, Gu K, Wang W, Xiang YB, Cheng J, Chen K, Zhang L, Zheng H, Shen CY, Huang CS, Hou MF, Shen H, Hu Z, Wang F, Deming SL, Kelley MC, Shrubsole MJ, Khoo US, Chan KY, Chan SY, Haiman CA, Henderson BE, Le Marchand L, Iwasaki M, Kasuga Y, Tsugane S, Matsuo K, Tajima K, Iwata H, Huang B, Shi J, Li G, Wen W, Gao YT, Lu W, Zheng W (2010) PLoS Genet 6(6): e1001002
    › Primary publication · 20585626 (PubMed) · PMC2891809 (PubMed Central)
28. Foamy cell angiosarcoma: a rare and deceptively bland variant of cutaneous angiosarcoma. Tatsas AD, Keedy VL, Florell SR, Simpson JF, Coffin CM, Kelley MC, Cates JM (2010) J Cutan Pathol 37(8): 901-6
    › Primary publication · 20175826 (PubMed)
29. Autofluorescence and diffuse reflectance spectroscopy and spectral imaging for breast surgical margin analysis. Keller MD, Majumder SK, Kelley MC, Meszoely IM, Boulos FI, Olivares GM, Mahadevan-Jansen A (2010) Lasers Surg Med 42(1): 15-23
    › Primary publication · 20077490 (PubMed)
30. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA (2010) Clin Cancer Res 16(2): 681-90
    › Primary publication · 20068102 (PubMed) · PMC2892225 (PubMed Central)
31. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA (2010) Clin Cancer Res 16(1): 348-57
    › Primary publication · 20028756 (PubMed) · PMC3205975 (PubMed Central)
32. Comparison of autofluorescence, diffuse reflectance, and Raman spectroscopy for breast tissue discrimination. Majumder SK, Keller MD, Boulos FI, Kelley MC, Mahadevan-Jansen A (2008) J Biomed Opt 13(5): 054009
    › Primary publication · 19021389 (PubMed)
33. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL (2008) J Clin Oncol 26(6): 897-906
    › Primary publication · 18180460 (PubMed)
34. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC (2007) Magn Reson Imaging 25(1): 1-13
    › Primary publication · 17222711 (PubMed) · PMC2634832 (PubMed Central)
35. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA (2006) Clin Cancer Res 12(5): 1570-6
    › Primary publication · 16533783 (PubMed)
36. Selective use of intraoperative touch prep analysis of sentinel nodes in breast cancer. Forbes RC, Pitchford C, Simpson JF, Balch GC, Kelley MC (2005) Am Surg 71(11): 955-60; discussion 961-2
    › Primary publication · 16372615 (PubMed)
37. Accuracy of intraoperative gross examination of surgical margin status in women undergoing partial mastectomy for breast malignancy. Balch GC, Mithani SK, Simpson JF, Kelley MC (2005) Am Surg 71(1): 22-7; discussion 27-8
    › Primary publication · 15757052 (PubMed)
38. Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy do not enhance the accuracy of lymphatic mapping for breast cancer. Lawson LL, Sandler M, Martin W, Beauchamp RD, Kelley MC (2004) Am Surg 70(12): 1050-5; discussion 1055-6
    › Primary publication · 15663043 (PubMed)
39. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Kelley MC, Hansen N, McMasters KM (2004) Am J Surg 188(1): 49-61
    › Primary publication · 15219485 (PubMed)
40. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography uptake in a giant adrenal myelolipoma. Ludwig V, Rice MH, Martin WH, Kelley MC, Delbeke D (2002) Mol Imaging Biol 4(5): 355-8
    › Primary publication · 14537110 (PubMed)
41. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Balch GC, Mithani SK, Richards KR, Beauchamp RD, Kelley MC (2003) Ann Surg Oncol 10(6): 616-21
    › Primary publication · 12839845 (PubMed)
42. Sentinel lymph node detection and microstaging in vulvar carcinoma. Molpus KL, Kelley MC, Johnson JE, Martin WH, Jones HW (2001) J Reprod Med 46(10): 863-9
    › Primary publication · 11725728 (PubMed)
43. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB (2001) J Natl Cancer Inst 93(21): 1624-32
    › Primary publication · 11698566 (PubMed)
44. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL (2001) J Clin Oncol 19(4): 1176-82
    › Primary publication · 11181684 (PubMed)
45. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC, Turner RR (2000) J Clin Oncol 18(13): 2553-9
    › Primary publication · 10893286 (PubMed)
46. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E, Morton DL (1999) Ann Surg Oncol 6(5): 442-9
    › Primary publication · 10458681 (PubMed)
47. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Kelley MC, Jones RC, Gupta RK, Yee R, Stern S, Wanek L, Morton DL (1998) Cancer 83(7): 1355-61
    › Primary publication · 9762936 (PubMed)
48. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Ollila DW, Kelley MC, Gammon G, Morton DL (1998) Semin Surg Oncol 14(4): 328-36
    › Primary publication · 9588726 (PubMed)
49. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Kelley MC, Ollila DW, Morton DL (1998) Semin Surg Oncol 14(4): 283-90
    › Primary publication · 9588721 (PubMed)
50. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Ravindranath MH, Kelley MC, Jones RC, Amiri AA, Bauer PM, Morton DL (1998) Int J Cancer 75(1): 117-24
    › Primary publication · 9426699 (PubMed)
51. Update on active specific immunotherapy with melanoma vaccines. Conforti AM, Ollila DW, Kelley MC, Gammon G, Morton DL (1997) J Surg Oncol 66(1): 55-64
    › Primary publication · 9290695 (PubMed)
52. Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma. Ravindranath MH, Amiri AA, Bauer PM, Kelley MC, Essner R, Morton DL (1997) Cancer 79(9): 1686-97
    › Primary publication · 9128983 (PubMed)
53. Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le(a), sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine. Ravindranath MH, Bauer PM, Amiri AA, Miri SM, Kelley MC, Jones RC, Morton DL (1997) Anticancer Drugs 8(3): 217-24
    › Primary publication · 9095325 (PubMed)
54. Ketorolac prevents postoperative small intestinal ileus in rats. Kelley MC, Hocking MP, Marchand SD, Sninsky CA (1993) Am J Surg 165(1): 107-11; discussion 112
    › Primary publication · 8418685 (PubMed)
55. Vasoactive intestinal peptide and substance P receptor antagonists improve postoperative ileus. Espat NJ, Cheng G, Kelley MC, Vogel SB, Sninsky CA, Hocking MP (1995) J Surg Res 58(6): 719-23
    › Primary publication · 7540700 (PubMed)
56. Pharmacological characterization of high affinity choline transporters in primary neuronal cultures in rat brain. Kelley MC, Raizada MK, Meyer EM (1988) Neuropharmacology 27(8): 837-42
    › Primary publication · 3216963 (PubMed)

View full member profile

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword